Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted Oragenics and The Texas A&M University System U.S. Patent No. […]
Axel Sjöblad was appointed as Managing Director effective March 1, 2016 and has successfully focused on further expanding BioGaias sales capabilities. ”I am proud of the progress that has taken place at the company during […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company has submitted, and the Medicines and Healthcare products Regulatory Agency (MHRA) has cleared, a Clinical Trial […]
Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced it has closed on $1.8M in Series A financing to support the launch of its new microbiome […]
Most women will experience the discomfort that accompanies vaginal imbalance at some point in their lives. Everyday activities and stressors, from sex to tight clothing or even diet and medication, can all disrupt vaginal health. […]
Merck announced a collaboration with Washington University in St. Louis, Missouri, USA, that could lead to the optimizing of nutritional supplements to restore a healthy gut microbial community (microbiome). The two-year collaboration will employ Merck’s […]
Corporate Leadership Transition: On May 10, 2018, Synlogic announced a CEO transition; Chief Medical Officer, Aoife Brennan, M.B., B.Ch., was appointed to serve as Interim President and Chief Executive Officer as successor to Jose-Carlos […]
Thryve, providers of high quality microbiotics and microbiome testing, announced today it has secured $1.4 million in funding. Participating investment firms include PivotNorth Capital, Unilever Ventures, Darling Ventures, Candela Paramount, Abstract Ventures and Joyance Partners. […]
Chr. Hansen completed a clinical trial1 using a carefully selected probiotic strain. Reaching both the primary and secondary end points of the trial, the results show a robust protective effect against gastrointestinal (GI) side effects […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced that Aoife Brennan, M.B., B.Ch., has accepted the position of Interim President and Chief Executive […]
Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In […]